Overview
At Global Regulatory Partners (GRP), we understand that early regulatory strategy plays a critical role in the success of innovative drug development programs. For companies developing novel therapies—especially those with limited regulatory precedent—the FDA’s INTERACT meeting represents a valuable opportunity to engage with the Agency at a formative stage.
INTERACT (Initial Targeted Engagement for Regulatory Advice on CBER- and CDER-Regulated Products) is designed to support early, focused dialogue between sponsors and FDA reviewers. When strategically utilized, it helps identify potential risks, refine development strategies, and establish a solid regulatory foundation before significant investments are made.
Introduction
In the increasingly complex regulatory landscape, early engagement with health authorities has become a critical success factor in drug development—especially for innovative and first-in-class therapies.
For companies navigating scientific uncertainty, novel technologies, or evolving regulatory expectations, establishing alignment with the FDA at an early stage can significantly influence development outcomes.
The FDA’s INTERACT meeting emerges as a strategic tool designed precisely for this purpose: enabling focused, early dialogue that helps sponsors validate their approach, identify risks, and build a solid regulatory foundation before advancing further into development.
What Is an FDA INTERACT Meeting?
An INTERACT meeting is a voluntary and non-binding interaction intended for very early-stage development programs, often occurring prior to a traditional pre-IND meeting.
Unlike later regulatory engagements, INTERACT is not focused on IND readiness. Instead, it emphasizes scientific feasibility and early regulatory alignment.
At this stage, FDA feedback helps sponsors address a key question:
Is the proposed product concept and development approach scientifically and regulatorily viable?
By clarifying expectations early, INTERACT meetings can significantly reduce uncertainties and improve development efficiency.
When Should You Request an INTERACT Meeting?
INTERACT meetings are particularly valuable for programs that:
- Involve advanced therapies such as cell and gene therapies or novel biologics
- Represent first-in-class or platform-based technologies
- Present complex nonclinical, CMC, or translational challenges
- Are developed by early-stage companies or academic spin-offs
The FDA actively encourages sponsors to leverage INTERACT for innovative or complex products where early guidance can shape the development strategy.
What Can Be Discussed?
INTERACT meetings focus on high-impact and strategic topics, including:
- Scientific rationale and product concept
- Early nonclinical development strategies
- Preliminary CMC and manufacturing considerations
- Identification of regulatory or translational risks
- High-level alignment on development pathways
At GRP, we emphasize clear, well-structured questions to ensure feedback from the FDA is actionable and directly supports next steps.
What INTERACT Is Not
It is important to understand the limitations of INTERACT meetings. They are not intended for:
- Detailed IND-enabling toxicology program discussions
- Final clinical protocols or endpoint definitions
- Dose selection or IND readiness confirmation
As development progresses, sponsors typically transition to a pre-IND meeting for more detailed regulatory discussions.
The Strategic Value of INTERACT
When properly planned, INTERACT meetings can:
- Reduce early-stage scientific and regulatory uncertainty
- Avoid unnecessary or misaligned studies
- Improve prioritization of development activities
- Enable a more efficient pathway toward IND submission
Early alignment with FDA expectations is not only good regulatory practice—it is a strategic advantage.
GRP Perspective
At GRP, we consider INTERACT meetings a key inflection point in early drug development. When used effectively, they provide clarity, reduce risk, and support the development of a robust regulatory strategy aligned with long-term goals.
Planning an FDA INTERACT Meeting?
GRP supports innovative companies in planning, preparing, and executing INTERACT meetings—from defining the right questions to translating FDA feedback into a clear regulatory roadmap.
Conclusion
In an increasingly complex and innovation-driven landscape, early regulatory alignment is no longer optional—it is a strategic necessity.
FDA INTERACT meetings provide a unique opportunity to engage with the Agency at a stage where critical decisions are still being shaped. When approached with clear objectives and a well-defined strategy, these interactions can significantly reduce uncertainty, strengthen development plans, and support more efficient progression toward clinical milestones.
At GRP, we believe that the true value of early FDA engagement lies not only in the feedback received, but in how that feedback is translated into actionable, forward-looking strategies.
For innovative programs, INTERACT is more than an early conversation—it is a foundation for long-term regulatory success.
GRP can act as your local Agent & Register your product in U.S
Contact our team today to Inquire!
Email: info@globalregulatorypartners.com
Telephone : (+1) 781-672-4200
References
📩 Connect with us to discuss your INTERACT strategy.
About Global Regulatory Partners
Global Regulatory Partners Inc, (GRP) is an American company that provides regulatory affairs, clinical, quality and safety services to medical devices, pharmaceutical, cosmetic and Food Supplement companies globally.
GRP headquarters is located in Massachusetts USA and its main affiliates are located in China, Japan, Brazil, Mexico and South Korea. GRP helps many life science companies register their products in different countries in compliance with local regulations.